Do analysts recommend BFRI or TVGN?

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 843.40%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BFRI or TVGN more profitable?

Tevogen Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Tevogen Bio's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -25.66% -515.34% -53.91% Tevogen Bio N/A N/A -472.77%

Does the media favor BFRI or TVGN?

In the previous week, Tevogen Bio had 3 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Tevogen Bio and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.94 beat Tevogen Bio's score of 0.78 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TLPH or BFRI?

Talphera presently has a consensus price target of $3.00, suggesting a potential upside of 271.15%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, TLPH or BFRI?

Biofrontera has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 1,398.36 -$14.29M -$0.31 N/A Biofrontera $41.71M 0.26 -$10.54M -$0.97 N/A

Is TLPH or BFRI more profitable?

Talphera has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Talphera's return on equity of -92.98% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% Biofrontera -25.66% -515.34% -53.91%

Does the media refer more to TLPH or BFRI?

In the previous week, Talphera had 11 more articles in the media than Biofrontera. MarketBeat recorded 13 mentions for Talphera and 2 mentions for Biofrontera. Talphera's average media sentiment score of 1.14 beat Biofrontera's score of 0.94 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BGM or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, BGM or BFRI?

BGM Group has higher earnings, but lower revenue than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.65 -$1.44M N/A N/A Biofrontera $41.71M 0.26 -$10.54M -$0.97 N/A

Is BGM or BFRI more profitable?

BGM Group has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. BGM Group's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Biofrontera -25.66% -515.34% -53.91%

Does the media prefer BGM or BFRI?

In the previous week, BGM Group had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for BGM Group and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.94 beat BGM Group's score of 0.51 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BGM Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer BFRI or MIRA?

In the previous week, Biofrontera and Biofrontera both had 2 articles in the media. Biofrontera's average media sentiment score of 0.94 beat MIRA Pharmaceuticals' score of 0.47 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biofrontera (BFRI) Competitors

$0.86 -0.02 (-1.93%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$0.87 +0.01 (+0.70%)

As of 06/10/2026 06:54 PM Eastern

Compare

BFRI vs. TVGN, LTRN, TLPH, BGM, and MIRA

Should you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include Tevogen Bio (TVGN), Lantern Pharma (LTRN), Talphera (TLPH), BGM Group (BGM), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does Biofrontera compare to Tevogen Bio?

Biofrontera (NASDAQ:BFRI) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

In the previous week, Tevogen Bio had 3 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Tevogen Bio and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.94 beat Tevogen Bio's score of 0.78 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Tevogen Bio's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Tevogen Bio	N/A	N/A	-472.77%

Biofrontera has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.26	-$10.54M	-$0.97	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 843.40%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

10.1% of Biofrontera shares are owned by institutional investors. 4.8% of Biofrontera shares are owned by insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biofrontera beats Tevogen Bio on 10 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Lantern Pharma?

Biofrontera (NASDAQ:BFRI) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biofrontera had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Biofrontera's score of 0.94 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Positive
Lantern Pharma	Very Positive

Lantern Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Lantern Pharma's return on equity of -198.34% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Lantern Pharma	N/A	-198.34%	-129.08%

Biofrontera has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.26	-$10.54M	-$0.97	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market.

Summary

Biofrontera beats Lantern Pharma on 8 of the 14 factors compared between the two stocks.

How does Biofrontera compare to Talphera?

Talphera (NASDAQ:TLPH) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Talphera has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Talphera's return on equity of -92.98% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Biofrontera	-25.66%	-515.34%	-53.91%

37.7% of Talphera shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 4.8% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Talphera has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Talphera presently has a consensus price target of $3.00, suggesting a potential upside of 271.15%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,398.36	-$14.29M	-$0.31	N/A
Biofrontera	$41.71M	0.26	-$10.54M	-$0.97	N/A

In the previous week, Talphera had 11 more articles in the media than Biofrontera. MarketBeat recorded 13 mentions for Talphera and 2 mentions for Biofrontera. Talphera's average media sentiment score of 1.14 beat Biofrontera's score of 0.94 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Talphera beats Biofrontera on 11 of the 16 factors compared between the two stocks.

How does Biofrontera compare to BGM Group?

BGM Group (NASDAQ:BGM) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

BGM Group has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

BGM Group has higher earnings, but lower revenue than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.65	-$1.44M	N/A	N/A
Biofrontera	$41.71M	0.26	-$10.54M	-$0.97	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BGM Group had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for BGM Group and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.94 beat BGM Group's score of 0.51 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BGM Group has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. BGM Group's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Biofrontera	-25.66%	-515.34%	-53.91%

10.1% of Biofrontera shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 4.8% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BGM Group beats Biofrontera on 8 of the 13 factors compared between the two stocks.

How does Biofrontera compare to MIRA Pharmaceuticals?

Biofrontera (NASDAQ:BFRI) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.26	-$10.54M	-$0.97	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

In the previous week, Biofrontera and Biofrontera both had 2 articles in the media. Biofrontera's average media sentiment score of 0.94 beat MIRA Pharmaceuticals' score of 0.47 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MIRA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. MIRA Pharmaceuticals' return on equity of -140.82% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MIRA Pharmaceuticals beats Biofrontera on 7 of the 11 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.27M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-0.89	18.83	24.41	23.63
Price / Sales	0.26	294.36	502.20	102.41
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.96	8.00	10.30	6.70
Net Income	-$10.54M	$23.89M	$3.56B	$337.26M
7 Day Performance	-13.27%	-5.43%	-2.93%	-2.43%
1 Month Performance	-22.25%	-4.18%	-0.36%	0.19%
1 Year Performance	33.10%	36.70%	20.08%	23.16%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.59 of 5 stars	$0.86 -1.9%	N/A	+41.0%	$11.27M	$41.71M	N/A	70	Gap Down
TVGN Tevogen Bio	2.3873 of 5 stars	$10.60 -1.4%	$100.00 +843.4%	-82.9%	$44.10M	N/A	N/A	3
LTRN Lantern Pharma	1.527 of 5 stars	$3.88 +1.8%	N/A	+15.1%	$43.88M	N/A	N/A	20	Positive News Gap Up
TLPH Talphera	3.9539 of 5 stars	$0.81 -0.9%	$3.00 +271.1%	+58.5%	$41.95M	$30K	N/A	19	Positive News Analyst Upgrade Analyst Revision
BGM BGM Group	0.5609 of 5 stars	$0.42 +24.9%	N/A	-97.4%	$41.31M	$25.10M	N/A	298	News Coverage Short Interest Increase Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. TVGN, LTRN, TLPH, BGM, and MIRA

How does Biofrontera compare to Tevogen Bio?

Summary

How does Biofrontera compare to Lantern Pharma?

Summary

How does Biofrontera compare to Talphera?

Summary

How does Biofrontera compare to BGM Group?

Summary

How does Biofrontera compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. TVGN, LTRN, TLPH, BGM, and MIRA

How does Biofrontera compare to Tevogen Bio?

Which has more volatility and risk, BFRI or TVGN?

Does the media favor BFRI or TVGN?

Is BFRI or TVGN more profitable?

Which has stronger earnings and valuation, BFRI or TVGN?

Do analysts recommend BFRI or TVGN?

Do institutionals and insiders hold more shares of BFRI or TVGN?

Summary

How does Biofrontera compare to Lantern Pharma?

Do analysts rate BFRI or LTRN?

Does the media favor BFRI or LTRN?

Is BFRI or LTRN more profitable?

Which has stronger earnings & valuation, BFRI or LTRN?

Do insiders and institutionals have more ownership in BFRI or LTRN?

Which has more volatility and risk, BFRI or LTRN?

Summary

How does Biofrontera compare to Talphera?

Is TLPH or BFRI more profitable?

Do insiders & institutionals hold more shares of TLPH or BFRI?

Which has more risk & volatility, TLPH or BFRI?

Do analysts rate TLPH or BFRI?

Which has preferable earnings and valuation, TLPH or BFRI?

Does the media refer more to TLPH or BFRI?

Summary

How does Biofrontera compare to BGM Group?

Which has more volatility & risk, BGM or BFRI?

Which has stronger valuation and earnings, BGM or BFRI?

Do analysts rate BGM or BFRI?

Does the media prefer BGM or BFRI?

Is BGM or BFRI more profitable?

Do institutionals and insiders hold more shares of BGM or BFRI?

Summary

How does Biofrontera compare to MIRA Pharmaceuticals?

Which has better valuation & earnings, BFRI or MIRA?

Does the media prefer BFRI or MIRA?

Which has more volatility and risk, BFRI or MIRA?

Is BFRI or MIRA more profitable?

Do institutionals & insiders hold more shares of BFRI or MIRA?

Do analysts rate BFRI or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools